Literature DB >> 19650873

A novel fluorescent alpha-conotoxin for the study of alpha7 nicotinic acetylcholine receptors.

Arik J Hone1, Paul Whiteaker, Sean Christensen, Yingxian Xiao, Erin L Meyer, J Michael McIntosh.   

Abstract

Homomeric alpha7 nicotinic acetylcholine receptors are a well-established, pharmacologically distinct subtype. The more recently identified alpha9 subunit can also form functional homopentamers as well as alpha9alpha10 heteropentamers. Current fluorescent probes for alpha7 nicotinic ACh receptors are derived from alpha-bungarotoxin (alpha-BgTx). However, alpha-BgTx also binds to alpha9* and alpha1* receptors which are coexpressed with alpha7 in multiple tissues. We used an analog of alpha-conotoxin ArIB to develop a highly selective fluorescent probe for alpha7 receptors. This fluorescent alpha-conotoxin, Cy3-ArIB[V11L;V16A], blocked ACh-evoked alpha7 currents in Xenopus laevis oocytes with an IC(50) value of 2.0 nM. Observed rates of blockade were minute-scale with recovery from blockade even slower. Unlike FITC-conjugated alpha-BgTx, Cy3-ArIB[V11L;V16A] did not block alpha9alpha10 or alpha1beta1deltaepsilon receptors. In competition binding assays, Cy3-ArIB[V11L;V16A] potently displaced [(125)I]-alpha-BgTx binding to mouse hippocampal membranes with a K(i) value of 21 nM. Application of Cy3-ArIB[V11L;V16A] resulted in specific punctate labeling of KXalpha7R1 cells but not KXalpha3beta2R4, KXalpha3beta4R2, or KXalpha4beta2R2 cells. This labeling could be abolished by pre-treatment with alpha-cobratoxin. Thus, Cy3-ArIB[V11L;V16A] is a novel and selective fluorescent probe for alpha7 receptors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19650873      PMCID: PMC2749889          DOI: 10.1111/j.1471-4159.2009.06299.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  51 in total

Review 1.  Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system.

Authors:  John A Dani; Daniel Bertrand
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

Review 2.  Targeting the alpha9alpha10 nicotinic acetylcholine receptor to treat severe pain.

Authors:  Michelle Vincler; J Michael McIntosh
Journal:  Expert Opin Ther Targets       Date:  2007-07       Impact factor: 6.902

3.  Evaluating the suitability of nicotinic acetylcholine receptor antibodies for standard immunodetection procedures.

Authors:  N Moser; N Mechawar; I Jones; A Gochberg-Sarver; A Orr-Urtreger; M Plomann; R Salas; B Molles; L Marubio; U Roth; U Maskos; U Winzer-Serhan; J-P Bourgeois; A-M Le Sourd; M De Biasi; H Schröder; J Lindstrom; A Maelicke; J-P Changeux; A Wevers
Journal:  J Neurochem       Date:  2007-04-10       Impact factor: 5.372

4.  The alpha10 nicotinic acetylcholine receptor subunit is required for normal synaptic function and integrity of the olivocochlear system.

Authors:  Douglas E Vetter; Eleonora Katz; Stéphane F Maison; Julián Taranda; Sevin Turcan; Jimena Ballestero; M Charles Liberman; A Belén Elgoyhen; Jim Boulter
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-12       Impact factor: 11.205

5.  Genetic approaches identify differential roles for alpha4beta2* nicotinic receptors in acute models of antinociception in mice.

Authors:  M I Damaj; C Fonck; M J Marks; P Deshpande; C Labarca; H A Lester; A C Collins; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  2007-03-19       Impact factor: 4.030

6.  Immunohistochemical detection of nicotinic acetylcholine receptor subunits alpha9 and alpha10 in rat lung isografts and allografts.

Authors:  Simone Biallas; Sigrid Wilker; Katrin S Lips; Wolfgang Kummer; Sergei A Grando; Winfried Padberg; Veronika Grau
Journal:  Life Sci       Date:  2007-02-01       Impact factor: 5.037

7.  Administration of keratinocyte growth factor (KGF) modulates the pulmonary expression of nicotinic acetylcholine receptor subunits alpha7, alpha9 and alpha10.

Authors:  Veronika Grau; Sigrid Wilker; Petra Hartmann; Katrin S Lips; Sergei A Grando; Winfried Padberg; Heinz Fehrenbach; Wolfgang Kummer
Journal:  Life Sci       Date:  2007-01-23       Impact factor: 5.037

8.  Central role of alpha9 acetylcholine receptor in coordinating keratinocyte adhesion and motility at the initiation of epithelialization.

Authors:  Alex I Chernyavsky; Juan Arredondo; Douglas E Vetter; Sergei A Grando
Journal:  Exp Cell Res       Date:  2007-07-20       Impact factor: 3.905

9.  Ryanodine is a positive modulator of acetylcholine receptor gating in cochlear hair cells.

Authors:  Javier Zorrilla de San Martín; Jimena Ballestero; Eleonora Katz; A Belén Elgoyhen; Paul A Fuchs
Journal:  J Assoc Res Otolaryngol       Date:  2007-07-24

Review 10.  The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation.

Authors:  W J de Jonge; L Ulloa
Journal:  Br J Pharmacol       Date:  2007-05-14       Impact factor: 8.739

View more
  18 in total

1.  Positional scanning mutagenesis of α-conotoxin PeIA identifies critical residues that confer potency and selectivity for α6/α3β2β3 and α3β2 nicotinic acetylcholine receptors.

Authors:  Arik J Hone; Miguel Ruiz; Mick'l Scadden; Sean Christensen; Joanna Gajewiak; Layla Azam; J Michael McIntosh
Journal:  J Biol Chem       Date:  2013-07-11       Impact factor: 5.157

2.  Onset of cholinergic efferent synaptic function in sensory hair cells of the rat cochlea.

Authors:  Isabelle Roux; Eric Wersinger; J Michael McIntosh; Paul A Fuchs; Elisabeth Glowatzki
Journal:  J Neurosci       Date:  2011-10-19       Impact factor: 6.167

3.  Embryonic toxin expression in the cone snail Conus victoriae: primed to kill or divergent function?

Authors:  Helena Safavi-Hemami; William A Siero; Zhihe Kuang; Nicholas A Williamson; John A Karas; Louise R Page; David MacMillan; Brid Callaghan; Shiva Nag Kompella; David J Adams; Raymond S Norton; Anthony W Purcell
Journal:  J Biol Chem       Date:  2011-04-19       Impact factor: 5.157

4.  α-Conotoxin PeIA[S9H,V10A,E14N] potently and selectively blocks α6β2β3 versus α6β4 nicotinic acetylcholine receptors.

Authors:  Arik J Hone; Mick'l Scadden; Joanna Gajewiak; Sean Christensen; Jon Lindstrom; J Michael McIntosh
Journal:  Mol Pharmacol       Date:  2012-08-22       Impact factor: 4.436

5.  Development of fluorescence imaging probes for nicotinic acetylcholine α4β2 receptors.

Authors:  Gurleen K Samra; Irakli Intskirveli; Anitha P Govind; Christopher Liang; Ronit Lazar; William N Green; Raju Metherate; Jogeshwar Mukherjee
Journal:  Bioorg Med Chem Lett       Date:  2017-12-17       Impact factor: 2.823

6.  Nicotinic acetylcholine receptors in dorsal root ganglion neurons include the α6β4* subtype.

Authors:  Arik J Hone; Erin L Meyer; Melissa McIntyre; J Michael McIntosh
Journal:  FASEB J       Date:  2011-10-24       Impact factor: 5.191

7.  Alexa Fluor 546-ArIB[V11L;V16A] is a potent ligand for selectively labeling alpha 7 nicotinic acetylcholine receptors.

Authors:  Arik J Hone; Paul Whiteaker; Jesse L Mohn; Michele H Jacob; J Michael McIntosh
Journal:  J Neurochem       Date:  2010-05-18       Impact factor: 5.372

8.  α9- and α7-containing receptors mediate the pro-proliferative effects of nicotine in the A549 adenocarcinoma cell line.

Authors:  Vanessa Mucchietto; Francesca Fasoli; Susanna Pucci; Milena Moretti; Roberta Benfante; Annalisa Maroli; Simona Di Lascio; Cristiano Bolchi; Marco Pallavicini; Cheryl Dowell; Michael McIntosh; Francesco Clementi; Cecilia Gotti
Journal:  Br J Pharmacol       Date:  2017-09-08       Impact factor: 8.739

9.  α-Conotoxins Identify the α3β4* Subtype as the Predominant Nicotinic Acetylcholine Receptor Expressed in Human Adrenal Chromaffin Cells.

Authors:  Arik J Hone; J Michael McIntosh; Layla Azam; Jon Lindstrom; Linda Lucero; Paul Whiteaker; Juan Passas; Jesús Blázquez; Almudena Albillos
Journal:  Mol Pharmacol       Date:  2015-09-01       Impact factor: 4.436

10.  On-resin strategy to label α-conotoxins: Cy5-RgIA, a potent α9α10 nicotinic acetylcholine receptor imaging probe.

Authors:  Markus Muttenthaler; Simon T Nevin; Marco Inserra; Richard J Lewis; David J Adams; Paul Alewood
Journal:  Aust J Chem       Date:  2019-12-03       Impact factor: 1.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.